BioAtla Inc. (NASDAQ:BCAB) went down by -7.10% from its latest closing price compared to the recent 1-year high of $76.63. The company’s stock price has collected -19.64% of loss in the last five trading sessions. Press Release reported on 01/10/22 that BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo(R) (nivolumab) for Treatment of Solid Tumors
Is It Worth Investing in BioAtla Inc. (NASDAQ :BCAB) Right Now?
Opinions of the stock are interesting as 5 analysts out of 5 who provided ratings for BioAtla Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $68.80, which is $54.15 above the current price. BCAB currently public float of 27.90M and currently shorts hold a 11.07% ratio of that float. Today, the average trading volume of BCAB was 241.40K shares.
BCAB’s Market Performance
BCAB stocks went down by -19.64% for the week, with a monthly drop of -30.57% and a quarterly performance of -44.65%, while its annual performance rate touched -64.13%. The volatility ratio for the week stands at 10.42% while the volatility levels for the past 30 days are set at 8.74% for BioAtla Inc.. The simple moving average for the period of the last 20 days is -23.43% for BCAB stocks with a simple moving average of -59.49% for the last 200 days.
Analysts’ Opinion of BCAB
Many brokerage firms have already submitted their reports for BCAB stocks, with BTIG Research repeating the rating for BCAB by listing it as a “Buy.” The predicted price for BCAB in the upcoming period, according to BTIG Research is $68 based on the research report published on October 15th of the previous year 2021.
ROTH Capital, on the other hand, stated in their research note that they expect to see BCAB reach a price target of $75. The rating they have provided for BCAB stocks is “Buy” according to the report published on June 28th, 2021.
Credit Suisse gave a rating of “Outperform” to BCAB, setting the target price at $68 in the report published on May 05th of the previous year.
BCAB Trading at -37.60% from the 50-Day Moving Average
After a stumble in the market that brought BCAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.88% of loss for the given period.
Volatility was left at 8.74%, however, over the last 30 days, the volatility rate increased by 10.42%, as shares sank -32.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.88% lower at present.
During the last 5 trading sessions, BCAB fell by -19.64%, which changed the moving average for the period of 200-days by -71.94% in comparison to the 20-day moving average, which settled at $18.77. In addition, BioAtla Inc. saw -25.37% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at BCAB starting from WALDRON RICHARD A, who sale 1,434 shares at the price of $21.76 back on Dec 02. After this action, WALDRON RICHARD A now owns 134,469 shares of BioAtla Inc., valued at $31,198 using the latest closing price.
Vasquez Christian, the See Remarks of BioAtla Inc., sale 200 shares at $21.76 during a trade that took place back on Dec 02, which means that Vasquez Christian is holding 25,259 shares at $4,351 based on the most recent closing price.
Stock Fundamentals for BCAB
Current profitability levels for the company are sitting at:
- -7016.08 for the present operating margin
The net margin for BioAtla Inc. stands at -8357.34. The total capital return value is set at -34.84, while invested capital returns managed to touch -43.96. Equity return is now at value -43.40, with -36.50 for asset returns.
Based on BioAtla Inc. (BCAB), the company’s capital structure generated 0.32 points at debt to equity in total, while total debt to capital is 0.32. Total debt to assets is 0.28, with long-term debt to equity ratio resting at 0.32. Finally, the long-term debt to capital ratio is 0.32.
When we switch over and look at the enterprise to sales, we see a ratio of 1,180.88, with the company’s debt to enterprise value settled at 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.46.